Effects of Natural Sourdough Fermentation Duration and Acid Development on Postprandial Blood Glucose in Prediabetic Adults
NCT06925451
Recruiting
The primary intervention for management of prediabetes is lifestyle changes. Eating healthier and increasing physical activity was found to slow the progression of prediabetes into diabetes, reduce the risk of other diseases like cardiovascular disease and hypertension, and have a lasting impact even after the intervention is discontinued. Studies found that increasing the intake of fiber, pre- and probiotics, and fermented foods have been linked to improved glycemic biomarkers. The goal of this... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/06/2025
Locations: 850 PBC, Phoenix, Arizona
Conditions: Insulin Resistance
Register for Updates
Carfilzomib Based Chemotherapy Mobilization for Autologous Stem Cell Transplants in Multiple Myeloma
NCT03909412
Recruiting
This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulating factor (G-CSF)
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Hackensack Meridian Health - John Theurer Cancer Center, Hackensack, New Jersey
Conditions: Multiple Myeloma
Register for Updates
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
NCT04840589
Recruiting
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland +6 locations
Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
Register for Updates
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
NCT05419024
Recruiting
Background: Human immunodeficiency virus (HIV) infects CD4 T cells. There is no cure for HIV. People with HIV need to take daily medications called antiretroviral therapy (ART) to control their infection. ART stops HIV from infecting cells, but HIV does not go away. Some infected cells remain. If ART is stopped, then HIV levels will rise and infect more cells. Objective: To find where HIV-infected cells are located in the body, even when ART is keeping levels low. Eligibility: Adults aged 1... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
04/04/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: HIV
Register for Updates
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT05952024
Recruiting
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.
Gender:
ALL
Ages:
Between 65 years and 99 years
Trial Updated:
04/04/2025
Locations: Research Site, La Jolla, California +51 locations
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
A Study of RM-718 in Healthy Subjects and in Patients With HO
NCT06239116
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and PK of RM-718 in healthy subjects with obesity and in patients with hypothalamic obesity (HO).
Gender:
ALL
Ages:
Between 12 years and 65 years
Trial Updated:
04/04/2025
Locations: UAB Pediatric Endocrinology, Birmingham, Alabama +6 locations
Conditions: Hypothalamic Obesity
Register for Updates
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT06433947
Recruiting
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Banner MD Anderson, Gilbert, Arizona +7 locations
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Usefulness and Feasibility of Ultrasound in Office Laryngology Procedures
NCT06579989
Recruiting
Investigators will assess the usefulness of using ultrasound in office procedures for laryngology interventions. Participants who qualify will be adults who are undergoing superior laryngeal nerve block, injection laryngoplasty, swallowing evaluation, voice evaluation and voice therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine, New York, New York
Conditions: Cough, Vocal Cord Atrophy, Vocal Cord Paresis, Vocal Cord Paralysis, Dysphagia, Dysphonia
Register for Updates
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
NCT06829238
Recruiting
This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Register for Updates
Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
NCT03992729
Recruiting
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to tildrakizumab during pregnancy to treat an approved indication. The pregnancy registry cohort study will be conducted by the Organization of Teratology Information Specialists (OTIS), which is a network of university and health department based information centers serving pregnant women and healthcare providers throughout North America. Th... Read More
Gender:
FEMALE
Ages:
All
Trial Updated:
04/04/2025
Locations: Christina Chambers, San Diego, California
Conditions: Pregnancy Related
Register for Updates
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning
NCT04889144
Recruiting
This trial tests whether Planning for Your Advance Care Needs (PLAN) intervention works to enhance Latino patients' understanding of and engagement in advanced care planning. The PLAN intervention may be an effective method to help people with cancer plan for and talk about advance care planning (the care they would want if they were unable to communicate) with their loved ones and doctors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine, New York, New York +3 locations
Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Register for Updates
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926
Recruiting
The VOYAGER study is a primary data collection, non-interventional, prospective, multinational, multicenter study. It is designed to collect real-world, long-term data to explore long-term effectiveness, safety, clinical insights, treatment patterns, and factors driving the treatment decisions among patients being treated with specified Roche ophthalmology products in approved retinal indications (Faricimab for neovascular age-related macular degeneration \[nAMD\], diabetic macular edema \[DME\]... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Retinal Research Institute, LLC, Phoenix, Arizona +236 locations
Conditions: Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Hemi-retinal Vein Occlusion
Register for Updates